OPKO Health Q4 revenue falls

OPKO Health

26/02/2026 22:00

Overview

Biopharmaceutical firm's Q4 revenue fell yr/yr due to asset sales

Company reported Q4 operating loss of $38.3 mln

Outlook

OPKO Health expects Q1 2026 total revenue between $125 mln and $140 mln

Company projects full-year 2026 revenue between $530 mln and $560 mln

OPKO Health anticipates 2026 R&D expenses between $125 mln and $135 mln

Result Drivers

ASSET SALES - Revenue decline attributed to sale of BioReference assets, impacting diagnostics revenue

COLLABORATION WITH REGENERON - Partnership with Regeneron led to upfront payment and potential milestone payments

Company press release: ID:nGNX8KmvHN

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue from Services
$71.1 mln
Q4 Net Income
-$31.3 mln
Q4 Operating Income
-$38.3 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for OPKO Health Inc is $3.00, about 154.2% above its February 25 closing price of $1.18

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)